Quarterly report [Sections 13 or 15(d)]

Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Castle Creek (Details)

v3.26.1
Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Castle Creek (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Feb. 24, 2025
Feb. 28, 2025
USD ($)
$ / shares
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2026
USD ($)
Dec. 31, 2025
USD ($)
Agreements          
Long-term royalty and commercial payment receivables under the cost recovery method       $ 55,886 $ 55,888
Short-term royalty and commercial payment receivables under the cost recovery method       0 0
Payments of consideration under RPAs, AAAs and CPPAs     $ 8,000    
Fair value of warrants       709 $ 697
Royalty Financing Transaction | Castle Creek Biosciences, Inc          
Agreements          
Rights entity acquired as a percentage of specified percentage 6.70% 6.70%      
Percentage of domestic sales   8.75%      
Percentage of worldwide sales   8.00%      
Percentage of proceeds from potential PRV   20.00%      
Number of warrants received | shares   10,464      
Exercise price of warrants received (in dollars per share) | $ / shares   $ 215.03      
Term of warrants received   10 years      
Aggregate purchase price   $ 5,000      
Long-term royalty and commercial payment receivables under the cost recovery method   $ 4,400      
Short-term royalty and commercial payment receivables under the cost recovery method       0  
Allowance for credit losses       0  
Fair value of warrants       $ 700  
Period between issuance and expiration   4 years 3 months      
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Volatility          
Agreements          
Derivative Asset, Measurement Input   126.6      
Royalty Financing Transaction | Castle Creek Biosciences, Inc | Risk-free interest rate          
Agreements          
Derivative Asset, Measurement Input   3.88